Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies

Alejandro Olivares-Hernández; Luis Figuero-Pérez; Eduardo Terán-Brage; Álvaro López-Gutiérrez; Álvaro Tamayo Velasco; Rogelio González Sarmiento; Juan Jesús Cruz-Hernández; José Pablo Miramontes-González

doi:10.3390/jcm10091919

Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies

J Clin Med. 2021 Apr 28;10(9):1919. doi: 10.3390/jcm10091919.

Authors

Affiliations

¹ Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain.
² Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
³ Department of Haematology, University Hospital of Valladolid, 47003 Valladolid, Spain.
⁴ Department of Medicine, University of Salamanca, 37007 Salamanca, Spain.
⁵ Department of Internal Medicine, University Hospital Rio Hortega, 47012 Valladolid, Spain.
⁶ Department of Medicine, University of Valladolid, 45005 Valladolid, Spain.

Abstract

Myeloid-derived suppressor cells (MDSCs) are a set of immature myeloid lineage cells that include macrophages, granulocytes, and dendritic cell precursors. This subpopulation has been described in relation to the tumour processes at different levels, including resistance to immunotherapy, such as immune checkpoint inhibitors (ICIs). Currently, multiple studies at the preclinical and clinical levels seek to use this cell population for the treatment of different haematological neoplasms, together with ICIs. This review addresses the different points in ongoing studies of MDSCs and ICIs in haematological malignancies and their future significance in routine clinical practice.

Keywords: haematological malignancies; immune checkpoint inhibitors (ICIs); immune resistance; myeloid-derived suppressor cells (MDSCs).

Publication types

Review